Shidlovski/iStock via Getty Images Shares of Clearside Biomedical ( NASDAQ: CLSD ) fell 12% after the company reported Phase 2b data for its drug CLS-AX in the treatment of neovascular age-related macular degeneration, or wet AMD. The topline data showed 67% of CLS-AX recipients did not require any.
Back to Health Page
